Management AMD

 

Part 1:  Present: Imaging and management in AMD

Chairs: Anat Loewenstein, Israel & Paolo Lanzetta, Italy

 

Imaging/diagnosis/follow up

Speakers: Luis Arias Barquet, Spain, Alfredo Garcia-Layana, Spain, Paolo Lanzetta, Italy, Stela Vujosevic, Italy

 

1. OCT angiography biomarkers in neovascular (remission or activity) AMD

2. Imaging in dry AMD

3. Non-exudative CNV; To treat or not?  

4. Role of Microperimetry

 

Discussion

​

Treatment

Speakers: Rufino Silva, Portugal, Maria Cristina Parravano, Italy, Karina Berg, Norway, Anat Loewenstein, Israel, Patricia Udaondo, Spain

1. Managment of polipoydal lesions (Atlantic study)

2. Latest evidence: RIVAL study

3. TAE latest evidence with aflibercept (ALTAIR)

4. Brolucizumab  Inquire with Novartis

5. 2RT results in management of AMD: LEAD trial

 

Discussion

​

Part 2:  What´s next? What’s cooking in the industry kitchen

Chairs: Barruch Kupperman, USA & Jordi Mones, Spain

 

Speakers: Barruch Kupperman, USA, Jordi Mones, Spain, Francine Behar-Cohen, France, Cedric Francois, USA, Anat Loewenstein, Israel, Francesco Boscia, Italy

1. Abicipar  

2. Faricimab

3. Brimonidine in AMD

4. Update on Complement inhibition results

5. New studies in neovascular AMD (PDS,CCR3 nature)

6. RPE transplant and other approaches

​

Discussion

 

Advanced AMD

Chair: Usha Chakravarthy, UK

 

Speakers: Jordi Mones, Spain & Itay Chowers, Israel

 

Review the pathogenesis of AMD and the pathways to CNV and GA  

Examine current therapeutics and consider the long term outcomes and unmet need

Evaluate the current therapeutic pipeline critically assessing the appropriateness of targets

Designing new therapies with precision medicine in mind

 

Diabetic Macular Edema

Chairs: Patricia Udaondo, Spain & Stela Vujosevic, Italy

 

Imaging in DME

Speakers: Stela Vujosevic, Italy, Maria Cristina Parravano, Italy, Rufino Silva, Portugal

 

1. Prognostic and predictive biomarkers in DME

2. Microvascular changes as predictor for DME progression

3. Choroid as predictor for visual response to antiVEGF

4. How can we define chronic DME?

​

Discussion

 

DME Management

Speakers: Francesco Boscia, Italy, Albert Augustin, Germany / Usha Chakravarthy, UK, Anat Loewenstein, Israel, Patricia Udaondo, Spain, Paolo Lanzetta, Italy, Karina Berg, Norway

 

Role of laser for treatment of DME and DR in the intravitreal therapy era.

Real world evidence with fluocinolone implant in DME

Long term efficacy and safety of Dexamethasone implant for DME.

Real life outcomes of anti-VEGF therapy in DME: a review

Take home messages of Protocol T

Summary of EURETINA guidelines for DME.

 

Discussion

​

What is next in DME?

J. Pablo Velazquez-Martin, USA

1. Phase II trials that succeeded and fail for DME: angiopoietin vs Tie2

2. Phase 1 first-in-human study of KSI-301: a novel anti-VEGF antibody biopolymer conjugate (ABC) with extended durability  

3. Drugs in pipeline for DME.

​

Discussion

Diabetic Retinopathy

Chairs: Francesco Bandello, Italy, & Rufino Silva, Portugal

Speakers: Francesco Boscia, Italy, Javier Zarranz, Spain, Francesco Bandello, Italy, Rufino Silva, Portugal

​

1. Epidemiology and screening in DR

2. OCT-A in patients without diabetic retinopathy

3. Comparison of FA and OCTA in DR

4. Ultrawidefield swept-source OCTA in DR

5. Diabetic retinopathy treated with antiVEGF: results on clinical trials

6. Update on DRCR.net studies in DR

7. Is it safe to space out injections when you are treating PDR with anti-VEGF alone?

​

Discussion and clinical cases
 

Vein Occlusion

Chairs: Albert Augustin, Germany & Alfredo García-Layana, Spain

Speakers: Albert Augustin, Germany, Ibraheem EI Ghrably, Abu Dhabi, Alfredo García-Layana, Spain

1. Multimodal imaging

2. The LEAVO trial

3. Long term efficacy of steroids in management of macular edema in vein Occlusion

4. Latest evidence of anti VEGF in vein occlusion  

5. Laser in vein occlusion: when and for what?

 

Discussion

​

Myopia

Chairs: Jose García Arumí, Spain & Jose Maria Ruiz-Moreno, Spain 

Speakers: Jose Maria Ruiz-Moreno, Spain, Maria Cristina Parravano, Italy / Francesco ​Bandello Italy, 

Jose García-Arumí, Spain

1. Myopic maculopathy; new classification

2. Factors influencing visual acuity in patients receiving antiVEGF for myopic CNV

3. Update on myopic CNV management

4. When is surgery the option in myopic maculpathy? News on surgery in high myopic eyes.

​

Discussion
 

Uveitis

Chair: Ron Neumann, Israel

​

Long Term systemic effects of Immunosuppressive drugs

• Steroids

• TNF inhibitors

• Methotrexate

• Celcept

​

Discussion:

Total burden on health of systemic therapy

Topical/systemic drugs decision making

Allowing development of cataract vs. long term effects of systemic

The art of discontinuing systemic therapy

Vaccinations and epidemics in modern times and the immunosuppressed patient  

​

Artificial Intelligence & Deep learning: Present or future?

Chair: Tunde Peto, UK

Speakers: Javier Zarranz, Spain, Leopold Schmetterer, Singapore, Dimitri Azar, USA

​

1. Introduction to AI and Deep learning: present and future

2. Fight retina blindness.

3. Home vision testing  

4. Analysis in DR

5. Future in imaging. Functional Imaging

6. What is the position of industry in AI? (separated? Together?)

​

Discussion
 

Central Serous Choroidopathy

Chairs: Francine Behar Cohen, France & Jose María Ruiz Moreno, Spain

​

TBA
 

GENE Therapy

Chair: TBA

Speakers: Itay Chowers, Israel, Jordi Mones, Spain, Marc de Smet, Switzerland, Usha Chakravarthy, UK,

Dave Guyer, USA

​

1. Introduction to Gene and stem cell therapy

2. International AMD genomic consortium.

3. Stem cell therapy for AMD and Retinitis Pigmentosa. Where are we?

4. Gene therapy for inherited retinal distrophies

5. Gene therapy for AMD: RGX-314

6. Surgeon´s view of Gene therapy approach: future of robot assistance

​

Discussion
 

Drug Delivery

Chairs: Diane Tang Liu, USA & Uday Kompella, USA

Speakers: Arup Das, USA, Rocio Herrero-Varnell, Spain, Vittoria Raffa, Italy, Mark Vezina, Canada, Angel Montero Carcaboso, Spain, Michael W. Stewart, USA, Diane Tang-Liu, USA,

Uday Kompella, USA, Viral Kansara, USA

Diabetic Macular Edema: Pathophysiology and Novel Therapeutic Agents

Microspheres as therapeutic systems to treat retinal diseases

Nanoformulation as intraocular drug delivery system to target the posterior segment

TBA   

Targeted treatment of retinoblastoma with an oncolytic adenovirus

Extended Duration Anti-VEGF therapy: the Promises and Disappointments

Tunable duration of prolonged drug release from a novel formulation

Biodegradable intraocular implants

Clearside Biomedical, Inc., VP, Discovery

​

Inhibition of Diabetic Retinopathy

Chair: Arup Das

Renu Kowluru, USA,  Edward Feener, USA, Susanne Mohr, USA, Ashwath Jayagopal, Switzerland

Targeting G-proteins to inhibit Diabetic Retinopathy

Kallikrein-Kinin System in Diabetic Retinopathy - Novel Target

Targeting IL-6 Signaling to Intervene in the Progression of Diabetic Retinopathy

Combotherapy of Diabetic Retinopathy: Emerging Paradigm

 
Therapy of Retinal Angiogenesis

Chair: Arup Das

Subrata Chakarabarti, Canada, Julia Busik, USA, John Penn, USA, Debasish Sinha, USA

Non-coding RNA based Therapeutics

Control of Retinal Angiogenesis by modification of cell membrane lipid composition and membrane fluidity

TBA

Glial influence in the pathogenesis of Diabetic Retinopathy